News

ABL is pleased to announce two major updates on its HIV Genotyping Software applications : the full integration of the ViroScore® and DeepChek® software applications with Nadis the availability of a new web-based and disease-specific chromatogram editor

Meet us at MEDICA 2019 for Leveraging your Infectious Diseases Genotyping Capacities   Good morning, ABL will be attending the next MEDICA forum in Düsseldorf from 18 – 21 November 2019 (Hall 3 / A74).  We will be pleased to have a chance to meet you there and explain you in detail the SA…

FLAGSTAFF, Ariz., and LUXEMBOURG CITY, Luxembourg — Aug. 31 — Advanced Biological Laboratories (ABL) is expected to soon begin manufacturing of a compact, portable and affordable test for tuberculosis (TB), designed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hop…

Nous avons le plaisir de vous annoncer que l’intégration du logiciel ViroScore®-HIV (CE IVD) à la plateforme Nadis est disponible. Cette intégration permet à l’ensemble des utilisateurs Nadis de bénéficier de fonctionnalités avancées pour le génotypage du VIH: Synchronisation bidirectionnelle des do…

Advanced Biological Laboratories (ABL) S.A. and ILC – Hydrox SIA are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Latvia. See current channel partners.

Nous avons le plaisir de vous annoncer que l’intégration du logiciel ViroScore®-HIV (CE IVD) à la plateforme Nadis est bientôt disponible. Cette intégration va permettre à l’ensemble des utilisateurs Nadis de bénéficier de fonctionnalités avancées pour le génotypage du VIH telles que l…

ABL is pleased to announce the development and future release of the first version of MicrobioChek, a generic downstream analysis software intended to be used by microbiology laboratories for micro-organism related molecular analysis. Developed with the support of a RDI grant from the Ministry of th…

FLAGSTAFF, Ariz., LUXEMBOURG City, Luxembourg — In an important step toward eradicating tuberculosis (TB), the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories (ABL…

LUXEMBOURG VILLE, Luxembourg, and ROCHESTER, Minn. – Advanced Biological Laboratories (ABL), S.A., a Luxembourg-based diagnostics company and leader in virology genotyping, and Mayo Clinic Laboratories have announced a collaboration. The two organizations are working together to develop a clinical t…

ÉVRY, France and LUXEMBOURG City, Luxembourg (February 27th, 2019) – IntegraGen, a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, and Advanced Biological Laboratories (ABL), a leading integrated diagnostics…

ABL launches its Life Science division and starts the distribution of disruptive molecular biology instruments to be used for research purposes – Join our Early Access Program and get 30% discount on all UltraGene real time PCR systems! More information Join the program

Advanced Biological Laboratories (ABL) S.A. and ILC – Instrumentos de Laboratório e Científicos Lda are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Portugal. See current ch…

LUXEMBOURG VILLE, Luxembourg, December 27th, 2018 — Advanced Biological Laboratories (ABL) S.A. today announced the official launch of its Life Science division to provide on a worldwide basis, innovative solutions around molecular biology. It is also proud to announce the execution of a distr…

Advanced Biological Laboratories (ABL) S.A. and ELTA 90 Medical Science are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Serbia and Montenegro. See current channel partners.

New poster on HIV resistance to be presented at the HIV DART 2018 congress

We are pleased to announce that a new poster communication entitled “Clinical resistance to dolutegravir assessed by next-generation sequencing in patients pre-exposed to raltegravir” will be presented at the HIV DART and Emerging Viruses 2018 congress in Miami (USA, 27-29 November 2018)…